1
Home
Companies

Vor Biopharma

#9273

Rank

$70.52M

Marketcap

US United States

Country

Vor Biopharma
Leadership team

Dr. Robert Ang M.B.A., M.D., MBBS (Pres, CEO & Director)

Dr. Tirtha Chakraborty Ph.D. (Chief Scientific Officer)

Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. (Scientific Founder & Chairman of Scientific Advisory Board)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001817229
Traded as
VOR
Social Media
URL
https://www.vorbio.com
Overview
Location

Summary
History
Mission
Vision
Key Team
Recognition and Award
References
Summary
Vor Biopharma, Inc., a clinical-stage company, develops engineered hematopoietic stem cell (eHSC) therapies for cancer patients. It is developing VOR33, an eHSC product candidate that is in phase 1/2 to treat acute myeloid leukemia (AML) and other hematological malignancies. The company's VOR33 eHSCs lacks CD33, a protein that is expressed by AML blood cancer cells. The company's eHSCs targeted therapies, such as CAR-Ts, bispecific antibodies, and antibody-drug conjugates provide treatment for blood cancers. Vor Biopharma, Inc. has a collaboration agreement with Akron BioProducts to develop and manufacture cGMP nucleases. The company was incorporated in 2015 and is headquartered in Cambridge, Massachusetts.
History

Vor Biopharma was founded in 2017 in Cambridge, MA with an aim to develop safe and effective HSC-based therapies for devastating diseases. With inspiration from nature and the experience of their multidisciplinary team of experts, Vor Biopharma combines cutting-edge technologies and the power of human immune systems to develop novel treatments.

Mission
Our mission is to develop transformational therapies to cure severe, life-threatening diseases and to improve the lives of patients and their families.
Vision
Our vision is to establish Vor Biopharma as a leader in the field of cell and gene therapy, accelerating the development of safe, effective and broadly accessible treatments.
Key Team

Dr. Nathan D. Jorgensen M.B.A., Ph.D. (Chief Financial Officer)

Dr. Eyal C. Attar M.D. (Chief Medical Officer)

Ms. Tania Philipp (Chief People Officer)

Dr. Robert G. Pietrusko Pharm.D., Pharm. D. (Chief Regulatory & Quality Officer)

Mr. John C. King M.B.A. (Chief Commercial Officer)

Dr. Veit Schmelmer Ph.D. (Sr. VP of Program & Alliance Management)

Recognition and Awards
Vor Biopharma was recognized by the Catalyst Award of the Massachusetts Biotechnology Council in 2018 and the Fierce 15 Award in 2019.
References

https://in.investing.com/equities/vor-biopharma

https://finance.yahoo.com/quote/VOR/profile?p=VOR

https://www.crunchbase.com/organization/vor-biopharma

https://companiesmarketcap.com/

https://www.vorbio.com

Dive deeper into fresh insights across Business, Industry Leaders and Influencers, Organizations, Education, and Investors for a comprehensive view.

Vor Biopharma
Leadership team

Dr. Robert Ang M.B.A., M.D., MBBS (Pres, CEO & Director)

Dr. Tirtha Chakraborty Ph.D. (Chief Scientific Officer)

Dr. Siddhartha Mukherjee DPHIL, M.D., Ph.D. (Scientific Founder & Chairman of Scientific Advisory Board)

Products/ Services
Biotechnology, Health Care, Pharmaceutical
Number of Employees
100 - 500
Headquarters
Cambridge, Massachusetts, United States
Established
2016
Company Registration
SEC CIK number: 0001817229
Traded as
VOR
Social Media
URL
https://www.vorbio.com